Actinium Pharmaceuticals to Present at H.C. Wainwright Investment Conference

NEW YORK, Sept. 4, 2026 /CourierPR/ -- Actinium Pharmaceuticals, Inc., a leading developer of targeted radiotherapies, will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City. The company's CEO, Sandesh Seth, will deliver a presentation on September 14 from 3:00 to 3:30 p.m. Eastern Time.

Actinium, which focuses on innovative radioconjugates to enhance cancer treatment, will also offer one-on-one meetings with investors. The company's pipeline includes a range of therapies targeting solid tumors and hematologic malignancies, such as ATNM-400, a novel therapy with potential across multiple cancer types, and Actimab-A, a promising treatment for acute myeloid leukemia and myelodysplastic syndrome. Additionally, Actinium is developing targeted conditioning agents like Iomab-B for bone marrow transplants and Iomab-ACT for cell and gene therapy.

ATNM-400, a key part of the pipeline, targets a unique antigen not found in prostate-specific membrane antigen (PSMA) and has shown promising preclinical results in various cancers, including metastatic castration-resistant prostate cancer, non-small cell lung cancer, and breast cancer. Actimab-A has already demonstrated improved survival in relapsed or refractory acute myeloid leukemia and is advancing towards a Phase 2/3 trial, with further development ongoing through a Collaborative Research and Development Agreement (CRADA) with the National Cancer Institute.

The company holds approximately 250 patents and patent applications, including intellectual property related to the cyclotron-based production of Ac-225. Actinium's mission is to revolutionize cancer treatment through its expertise in tumor biology, translational medicine, and radiochemistry.

Actinium Pharmaceuticals, Inc. continues to advance its innovative radiotherapies and aims to improve patient outcomes in the treatment of various forms of cancer. The upcoming conference presentation will provide an update on the company's progress and future plans.